Esperion appoints Eric Warren as Chief Commercial Officer; salary $444K, bonus target 35%

Esperion Therapeutics, Inc.

Eric Warren appointed CCO effective March 1, 2022; he was previously VP US Sales and Marketing since Jan 2021.
Annual base salary $444,000; eligible for annual bonus targeted at 35% of base salary.
Severance: 1x base salary plus target bonus if terminated within 12 months after a Sale Event.
Outside Sale Event: severance of 9 months' base salary plus COBRA contribution.
Warren has experience at Sanofi, Merck, and Nabriva Therapeutics.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Eric Warren

Chief Commercial Officer

ESPR · Esperion Therapeutics, Inc.

Effective: 2022-03-01
Filed: March 1, 2022, 6:59 PM ET

On March 1, 2022, the board of directors (the “Board”) of Esperion Therapeutics, Inc. (the “Company”) appointed Eric Warren, R.Ph. as the Company’s Chief Commercial Officer pursuant to the terms of an employment agreement with Mr. Warren (the “Warren Agreement”), effective as of March 1, 2022 (the “Commencement Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Eric Warren was appointed as Chief Commercial Officer at Esperion Therapeutics, Inc..

Action: appointed
Role: Chief Commercial Officer

Exact text from the filing

On March 1, 2022, the board of directors (the “Board”) of Esperion Therapeutics, Inc. (the “Company”) appointed Eric Warren, R.Ph. as the Company’s Chief Commercial Officer pursuant to the terms of an employment agreement with Mr. Warren (the “Warren Agreement”), effective as of March 1, 2022 (the “Commencement Date”).

View on SEC.gov

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-004562

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.